Long-Term Survival and Myocardial Function Following Systemic Delivery of Delandistrogene Moxeparvovec in DMD MDX Rats
Human Gene Therapy · 2024
DOI: 10.1089/hum.2024.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, 2024. Verfasst von Stephen Baine und 10 weiteren Autor:innen. Beteiligte Einrichtung: Sarepta Therapeutics, Inc., Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Dystrophin, Genetic Vectors, Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Delandistrogene moxeparvovec is a gene transfer therapy for Duchenne muscular dystrophy (DMD) that uses an adeno-associated viral vector to deliver a micro-dystrophin transgene to skeletal and cardiac muscle. This study evaluated the long-term survival and cardiac efficacy of delandistrogene moxeparvovec in a DMD-mutated (DMD MDX ) rat model of DMD-related cardiomyopathy. DMD MDX male rats, aged 21–42 days, were injected with 1.33 × 10 14 viral genomes/kilogram (vg/kg) delandistrogene moxeparvovec and followed for 12, 24, and 52 weeks. Ambulation was recorded via the Photobeam Activity System, whereas echocardiograms, cardiomyocyte contractility, calcium handling, and histological analysis of fibrosis were used to evaluate cardiac disease at 12-, 24-, and 52-weeks post-treatment. A separate cohort of rats was used to assess the impact of delandistrogene moxeparvovec on survival. Treatment with delandistrogene moxeparvovec extended median survival in DMD MDX rats to >25 months versus the 13-month median survival in saline-control-treated DMD MDX rats. Compared with saline control, delandistrogene moxeparvovec therapy elicited statistically significant improvements across cardiac parameters approaching wild-type values with additional benefits in mobility, histopathology, and fibrosis observed. Transgene expression was maintained up to >25 months and micro-dystrophin expression was broadly distributed across skeletal and cardiac muscle. Taken together, these findings demonstrate long-term cardiac efficacy and improved survival following delandistrogene moxeparvovec treatment in DMD MDX rats.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sarepta Therapeutics, Inc., Cambridge, Massachusetts, USA.
Zitieren
APA
Baine, S., Wier, C., Lemmerman, L., Cooper-Olson, G., Kempton, A., Haile, A., Endres, J., Fedoce, A., Nesbit, E., Rodino-Klapac, L. R., & Potter, R. A. (2024). Long-Term Survival and Myocardial Function Following Systemic Delivery of Delandistrogene Moxeparvovec in DMD MDX Rats. Human Gene Therapy. https://doi.org/10.1089/hum.2024.013
Vancouver
Baine S, Wier C, Lemmerman L, Cooper-Olson G, Kempton A, Haile A, et al. Long-Term Survival and Myocardial Function Following Systemic Delivery of Delandistrogene Moxeparvovec in DMD MDX Rats. Human Gene Therapy. 2024. doi:10.1089/hum.2024.013
BibTeX
@article{Baine2024,
author = {Baine, Stephen and Wier, Chris and Lemmerman, Luke and Cooper-Olson, Grace and Kempton, Amber and Haile, Alex and Endres, Julian and Fedoce, Alessandra and Nesbit, Ellyn and Rodino-Klapac, Louise R and Potter, Rachael A},
title = {Long-Term Survival and Myocardial Function Following Systemic Delivery of Delandistrogene Moxeparvovec in DMD MDX Rats},
journal = {Human Gene Therapy},
year = {2024},
doi = {10.1089/hum.2024.013}
}
EUVIMED